Thermo Fisher Scientific ended its $12bn agreement to purchase Qiagen after its tender offer for the Dutch maker of medical testing equipment fell short, with activist investor Davidson Kempner Capital Management leading opposition to one of the biggest deals in the health sector in 2020.
Only about 47% of Qiagen shares were tendered, Thermo Fisher said in a statement on Thursday, meaning the minimum threshold for acceptance of the proposed deal had not been met. Qiagen will pay Thermo Fisher a reimbursement of $95m, according to the statement...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.